STAA (Staar Surgical Co) ROCE %: 18.00% (As of Mar. 2026)


STAA Staar Surgical Co STAA
79 GF Score
Price $29.50
GF Value $31.39
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Staar Surgical Co ROCE %?

Staar Surgical Co STAA -5.48% 79 ROCE % is 18.00% as of Mar. 2026. GuruFocus rates STAA with a GF Score™ of 79/100 and a GF Value™ of $31.39 (Fairly Valued). The stock has 7 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Staar Surgical Co's annualized ROCE % for the quarter that ended in Mar. 2026 was 18.00%.

Staar Surgical Co  (NAS:STAA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Staar Surgical Co ROCE % Related Terms

Staar Surgical Co ROCE % Historical Data

* Premium members only.

The historical data trend for Staar Surgical Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Staar Surgical Co ROCE % Chart

Staar Surgical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.99 13.19 7.11 -2.92 -11.17

Staar Surgical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -33.55 -25.76 25.29 -11.25 18.00
STAA
79GF Score
Staar Surgical Co STAA
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Staar Surgical Co ROCE % Calculation

Staar Surgical Co's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-45.946/( ( (509.524 - 70.306) + (451.678 - 68.504) )/ 2 )
=-45.946/( (439.218+383.174)/ 2 )
=-45.946/411.196
=-11.17 %

Staar Surgical Co's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=69.612/( ( (451.678 - 68.504) + (451.118 - 60.994) )/ 2 )
=69.612/( ( 383.174 + 390.124 )/ 2 )
=69.612/386.649
=18.00 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 18.00% mean?
Staar Surgical Co (STAA) has a ROCE % of 18.00% as of Mar. 2026.
Is Staar Surgical Co's ROCE % too high?
Staar Surgical Co's current ROCE % is 18.00%. The Medical Devices & Instruments industry median ROCE % is 2.23. Staar Surgical Co's value of 18.00% is 707.2% above this industry median. Overall, Staar Surgical Co has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Staar Surgical Co's ROCE % compare to NNNN and ATRC?
Staar Surgical Co's ROCE % of 18.00% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. Staar Surgical Co's value of 18.00% is 707.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Staar Surgical Co's current ROCE % of 18.00% is 707.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Staar Surgical Co's current ROCE % is 18.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Staar Surgical Co stock overvalued right now?
Based on GuruFocus' analysis, Staar Surgical Co (STAA) is currently considered Fairly Valued. The stock's GF Value™ is $31.39, compared to a current price of $29.50 — trading 6% below its estimated fair value. The current ROCE % is 18.00% and 707.2% above the Medical Devices & Instruments industry median of 2.23. Staar Surgical Co's overall GF Score™ is 79/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Staar Surgical Co (STAA), the current ROCE % is 18.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Staar Surgical Co (STAA) Overvalued in 2026?

Based on GuruFocus' analysis, Staar Surgical Co stock appears to be undervalued. The current stock price of $29.50 is trading 6% below its estimated GF Value™ of $31.39. GuruFocus considers Staar Surgical Co to be Fairly Valued.

Key valuation signals for STAA:

  • ROCE %: 18.00%
  • GF Value™: $31.39 vs. price of $29.50 (6% below fair value)
  • GF Score™: 79/100 with 7 warning signs
  • Industry Position: 707.2% above the Medical Devices & Instruments median

No single metric tells the full story. See the STAA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Staar Surgical Co Business Description

Other Exchanges SR3:Germany
Address 25510 Commercentre Drive, Lake Forest, CA, USA, 92630
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company offers two types of products: Implantable Collamer lenses (ICL), which are used in refractive surgery. The company generates almost all of its revenue from the sale of its ICL products. Geographically, the company generates key revenue from Foreign sales.
79GF Score

Get the complete analysis for STAA

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$29.50
Price
$31.39
GF Value